Don’t Forget — National Prescription Drug — Take Back Day is TOMORROW!

Read all about it here.

How long should therapy last?

I like this opin­ion arti­cle from the NY Times writ­ten by Jonathan Alpert, a psy­chother­a­pist prac­tic­ing in New York.

I don’t dis­agree with long — term psy­chother­apy when it’s the desire of the patient and within the skillset of the prac­ti­tioner.  It’s exactly what some patients want as they unravel com­pli­cated lives and com­pli­cated reac­tions to it.

But…

as ther­a­pists, we must face that some peo­ple want and need quick strate­gies that focus directly on prob­lem solving.

This often means defin­ing the prob­lem (which is dif­fer­ent than the chief com­plaint) and pur­su­ing treat­ment that increases the pos­si­bil­ity of solv­ing the prob­lem.  This is much dif­fer­ent than com­fort­ing the patient.  This is the money quote from the article:

… there’s a dif­fer­ence between feel­ing good and chang­ing your life. Feel­ing accepted and val­i­dated by your ther­a­pist doesn’t push you to reach your goals. To the con­trary, it might even encour­age you to stay mired in dys­func­tion. Ther­apy ses­sions can work like spa appoint­ments: they can be relax­ing but don’t nec­es­sar­ily help solve prob­lems. More than an oasis of kind­ness or a cozy hour of val­i­da­tion and accep­tance, most patients need smart strate­gies to help them achieve real­is­tic goals.

 

A good ther­a­pist can accom­plish this with­out antag­o­niz­ing the patient.  Good ther­a­pists bal­ance on the razor’s edge with keep­ing enough ten­sion in the air that rein­forces the need for change, all the while help­ing the patient’s self — con­fi­dence that change is pos­si­ble and necessary.

I do think the author should have men­tioned that cer­tain dis­or­ders may have both a treat­ment phase (an acute burst of ther­apy, with a goal on design­ing strate­gies that increase the pos­si­bil­ity for change) and a main­te­nance phase.  In a main­te­nance phase, espe­cially for chronic relaps­ing dis­or­ders like addic­tions, it can help to con­tinue reg­u­lar meet­ings with the goal of pre­serv­ing recov­ery rather than acute treat­ment.  This is often called “relapse pre­ven­tion” ther­apy.  Relapse pre­ven­tion helps the client main­tain recov­ery by focus­ing on pos­i­tive gains in treat­ment while mon­i­tor­ing for warn­ing signs of increas­ing addic­tion risk.

Club Drugs, Hallucinogens, and PCP

I have a new sem­i­nar online which you can find by going here.

This is the topic at the Uni­ver­sity of Col­orado Addic­tion Psy­chi­a­try lec­ture tomorrow.

It’s been updated to include infor­ma­tion about methe­drone, mephedrone, methy­lone aka Bath Salts, Plant Food, Pond Water Cleaner, Ivory Wave…

As always, feel free to con­tact me if you’re inter­ested in a pre­sen­ta­tion to your local group. Free in Denver!

 

Save lots of money (and get better anyway)

I just stum­bled across this arti­cle by Dr. Aaron Car­roll who writes at The Inci­den­tal Econ­o­mist and is also the author of books like

Don’t Swal­low Your Gum!: Myths, Half-Truths, and Out­right Lies About Your Body and Health

Read the entire post here if you are interested.

Basi­cally, there are new drugs which inno­vate, new drugs which repli­cate… and new drugs which obfus­cate.  That’s it for the rhymes today.

A good exam­ple, in my spe­cialty, is “new” Lexapro sits along “old” Celexa.  Lexapro is $$$.  Celexa costs $.  Drugs like Lexapro extend patent pro­tec­tion not by cre­at­ing a novel mol­e­cule but by mod­i­fy­ing Celexa just enough so that from the FDA’s stand­point it’s a new drug.  There is not one shred of evi­dence that Lexapro is bet­ter than Celexa, and don’t expect any — in the brain, Celexa and Lexapro are identical.

Another exam­ples is Pris­tiq (which is mod­i­fied Effexor).

If anybody’s inter­ested there’s a LOT to say about this but I’ll wait to see if there’s much inter­est in the topic.

 

The OxyContin Generation

Unlike most “gen­er­a­tions” which seg­re­gate based on a slice of the demo­graphic, I’d say the Oxy­Con­tin Gen­er­a­tion started in the late 1990s, includes every­body from near — teens to senior cit­i­zens, includes all races, all parts of the coun­try, and con­tin­ues today.  You might give it a dif­fer­ent name today — espe­cially since Oxy­Con­tin was refor­mu­lated and made more dif­fi­cult to abuse — but whether we rebrand it as the Vicodin gen­er­a­tion, the oxy­codone gen­er­a­tion… it’s all the same.

Prior to the 1990s, phar­ma­ceu­ti­cal opi­oid abuse was a known prob­lem, for sure, but the major opi­oid abuse epi­demic in the United States involved heroin.  For lots of rea­sons, both local to the United States (push for chronic pain enhance­ments, relax­ation of state boards of med­i­cine in their view of “over­pre­scrib­ing”) as well as geopo­lit­i­cal (believe it or not, the Tal­iban had a sharp role in reduc­ing the world’s sup­ply of opium/heroin), the drug of abuse pat­tern in the United States shifted quite dra­mat­i­cally from ille­gal opi­oids like heroin to sundry legal opi­oids like Oxy­Con­tin.  Oxy­Con­tin took parts of the east­ern United States by storm in the late 1990s, even earn­ing the name Hill­billy Heroin because of its surge of pop­u­lar­ity in Appalachia.

So, what are we left with now?  An epi­demic of phar­ma­ceu­ti­cal abuse that finds

Here’s an arti­cle from the NY Times that looks at how the bat­tle is being played out one patient at a time.  I like this arti­cle, because it focusses on the group caught in the cross­fire between an out — of — con­trol drug epi­demic and the vul­ner­a­ble patient pop­u­la­tion it’s created.

Youth Suicide Prevention

Did you know that…

  • About 15% of high­school­ers seri­ously con­sider suicide

and

  • Sui­cide is the third lead­ing cause of death in the 10 — 24 age group

This brief from the CDC high­lights the above facts and also points you towards very help­ful resources that help to assess, under­stand, and mon­i­tor the at — risk population.

 

 

 

Almost One Million Fewer Users of Cocaine in US 2005 — 2010

From the SAMHSA blog, here’s a sum­mary about the grad­ual reduc­tion in cocaine use in the United States.

 

The arti­cle doesn’t go into the many rea­sons that cocaine is less pop­u­lar.  Some of these are:

  • reduced Colom­bian production
  • ongo­ing large vol­ume inter­dic­tion at the Mex­i­can border
  • more ship­ments to Europe
  • all of the above make cocaine more expen­sive, while the US in an eco­nomic downturn
  • drugs have fads, just like fash­ion and pop cul­ture products

For more infor­ma­tion, check out my free pre­sen­ta­tion on Stim­u­lants.  This is the same pre­sen­ta­tion given at the Uni­ver­sity of Col­orado on April 4.

National Prescription Drug Take — Back Day is Saturday, April 28

Sat­ur­day, April 28, is National Pre­scrip­tion Drug Take — Back Day.  It’s spon­sored by the DEA and in part­ner­ship with local law enforce­ment as well as the Uni­ver­sity of Col­orado and other agencies.

The Take — Back Day in Novem­ber 2011 col­lected 188.5 tons (!!!) of unused and expired medications.

Since there is a glut of dan­ger­ous med­ica­tions sit­ting in the med­i­cine cab­i­nets all across the coun­try, tak­ing your unused and expired med­ica­tions for safe dis­posal is good for the envi­ron­ment, helps you avoid an acci­den­tal expo­sure, and reduces the chance that your child, neigh­bors, or vis­i­tors rum­mage through your home for drugs.

Metro — Den­ver loca­tions for the National Pre­scrip­tion Drug Take — Back Day can be found here.

New Stimulant seminar online

I’m teach­ing at the Uni­ver­sity of Col­orado Depart­ment of Psy­chi­a­try on Wednes­day.  Here’s a copy of the pre­sen­ta­tion.  The topic is Stim­u­lants.

If your orga­ni­za­tion would like train­ing on drug abuse, please let me know!

2 “medical” mariuana physicians arrested in Larimer County

From the Den­ver Post, here’s a brief news blurb about two docs arrested for allegedly hand­ing out phony mar­i­juana recommendations.

The doc­tors are Dr. Dal­las Wil­son and Dr. Joseph Montante.

As I’ve offered before, this is not a rare occur­rence.  Only a small per­cent­age of the “med­ical” mar­i­juana recip­i­ents are the infirm with chronic med­ical dis­abil­i­ties like glau­coma, can­cer, or chemother­apy induced nausea.